Our Neuroscience research & development (R&D) team is focused on developing innovations for clinically diverse populations with high unmet needs.
With numerous early-, mid-, and late-development programs currently underway, we are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for neuropsychiatric, neurodegenerative, and neurological autoantibody-driven diseases.
Our global clinical research capabilities for end-to-end development of potential treatments give us the flexibility to grow strong relationships.
We are working to bring greater precision to the development of an expanded, differentiated portfolio of novel medicines. Our robust pipeline is guided by our deepened understanding of mechanisms of key neurological disorders and our ability to identify distinct subpopulations within these diseases.